Transcatheter Aortic Valve Implantation (TAVI) Market by procedure (Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation) - Global Opportunities and Forecasts, 2014 - 2022

September 2016 | 120 pages | ID: T50E63EAA60EN
Allied Market Research

Abstracts

Transcatheter aortic valve implantation (TAVI), also called as transcatheter aortic valve replacement (TAVR), is a minimally invasive surgical procedure, wherein a diseased aortic valve is replaced with artificial valve through blood vessels. The procedure is designed to treat high-risk patients suffering from aortic stenosis. These high-risk patients refer to the patient population that are either inoperable or unfit to undergo surgical aortic valve replacement (SAVR) procedure. The older population (above 75 years of age) falls under the high-risk category, as the open heart surgery is too risky for them. TAVI involves implantation of transcatheter aortic valves to regenerate the blood circulation ability of the aortic valve.
The world TAVI market is driven by the rise in geriatric population that results in increase in prevalence of aortic stenosis, advancements in transcatheter aortic valves, and increase in adoption rate of TAVI devices. However, stringent and time-consuming government regulations for transcatheter aortic valves (being class III medical devices) and their high cost are set to restrain the market growth.

The report segments the TAVI market on the basis of procedure and geography. According to procedure, the market is classified into transfemoral, transapical, and transaortic implantation. On the geographical basis, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The TAVI market is highly competitive and consolidated in nature. Edwards Lifesciences Corporation, Medtronic plc, and St. Jude Medical, Inc. have dominated the overall market. These players have adopted product development as their key strategy, and hence launched several technologically advanced transcatheter aortic valves in the past few years. For instance, in March 2016, Direct Flow Medical, Inc. launched its next-generation DirecTrack TAVR delivery system in the European market. In the same year, Edwards Lifesciences Corporation received the Ministry of Health, Labour and Welfare (MHLW) approval for launch of its SAPIEN 3 transcatheter heart valve in the Japanese market. The market has also witnessed several approvals for clinical trials of transcatheter aortic valves. For instance, in June 2016, Medtronic plc received approval for its CoreValve Evolut R US Clinical Study.
Key players profiled in this report are:

• Boston Scientific Corporation
• Direct Flow medical, Inc.
• Edwards Lifesciences Corporation,
• HLT, Inc., JenaValve Technology, Inc.
• Medtronic plc
• Meril Life Sciences Pvt. Ltd.
• St. Jude Medical, Inc.
• SYMETIS SA
• Transcatheter Technologies GmbH.

KEY BENEFITS:

• This report provides an extensive analysis of the current trends, future estimations, and dynamics in the world TAVI market through 2014–2022, which assists to identify the prevailing opportunities.
• In-depth analysis is conducted by market estimations for the key segments for both value and volume.
• Comprehensive analysis of factors that drive and restrict the growth of the TAVI market is provided.
• An in-depth analysis of current research and clinical developments within the market is presented.

Key market players are profiled and their strategies are analyzed thoroughly, which interprets the competitive outlook of the world TAVI market.

KEY MARKET SEGMENTS:

By Procedure

• Transfemoral Implantation
• Transapical Implantation
• Transaortic Implantation

By Geography

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Switzerland
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Israel
• South Africa
• Saudi Arabia
• Rest of LAMEA

Contents

CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology
  1.4.1 Secondary Research
  1.4.2 Primary Research
  1.4.3 Analyst Tools and Models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings
  3.2.1 Top investment pockets
3.3 Porters Five Forces Analysis
  3.3.1 Bargaining power of suppliers
  3.3.2 Bargaining power of buyers
  3.3.3 Threat of new entrants
  3.3.4 Intensity of rivalry
  3.3.5 Threat of substitutes
3.4 Market share analysis, 2015
3.5 Government Regulations
  3.5.1 U.S. FDA
  3.5.2 Europe CE Mark
  3.5.3 Ministry of Health, Labour and Welfare (MHLW)
3.6 Reimbursement Scenario
3.7 Clinical Trials
3.8 Market dynamics
  3.8.1 Drivers
    3.8.1.1 Rise in prevalence of aortic stenosis coupled with increase in geriatric population
    3.8.1.2 Increase in adoption rate for transcatheter aortic valve implantation procedure
    3.8.1.3 Increasing clinical evidence of safety and efficacy and new device approvals
    3.8.1.4 Increase in number of TAVR Centers
  3.8.2 Restraints
    3.8.2.1 High cost of the device and unfavorable reimbursement policies
    3.8.2.2 Stringent regulatory approval process
  3.8.3 Opportunities
    3.8.3.1 Use of TAVI systems for new indications
    3.8.3.2 Rise in expenditure in healthcare and emergence in developing countries
    3.8.3.3 Increase in interest of local to global players in the TAvi market

CHAPTER 4 WORLD TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, BY PROCEDURE

4.1 Overview
  4.1.1 Key market trends
  4.1.2 Key growth factors and opportunities
  4.1.3 Market size and forecast
4.2 Transfemoral (TF) Implantation
  4.2.1 Market size and forecast
4.3 Transapical (TA) Implantation
  4.3.1 Market size and forecast
4.4 Transaortic Implantation
  4.4.1 Market size and forecast

CHAPTER 5 WORLD TRANSCATHTER AORTIC VALVE IMPLANTATION MARKET, BY GEOGRAPHY, 2014-2022

5.1 Overview
  5.1.1 Market size and forecast
5.2 North America
  5.2.1 Key market trends
  5.2.2 Key growth factors and opportunities
  5.2.3 Market size and forecast
  5.2.4 U.S.
    5.2.4.1 Market size and forecast
  5.2.5 Canada
    5.2.5.1 Market size and forecast
  5.2.6 Mexico
    5.2.6.1 Market size and forecast
5.3 Europe
  5.3.1 Key market trends
  5.3.2 Key growth factors and opportunities
  5.3.3 Market size and forecast
  5.3.4 Germany
    5.3.4.1 Market size and forecast
  5.3.5 France
    5.3.5.1 Market size and forecast
  5.3.6 UK
    5.3.6.1 Market size and forecast
  5.3.7 Italy
    5.3.7.1 Market size and forecast
  5.3.8 Switzerland
    5.3.8.1 Market size and forecast
  5.3.9 Rest of Europe
    5.3.9.1 Market size and forecast
5.4 Asia-Pacific
  5.4.1 Key market trends
  5.4.2 Key growth factors and opportunities
  5.4.3 Market size and forecast
  5.4.4 India
    5.4.4.1 Market size and forecast
  5.4.5 China
    5.4.5.1 Market size and forecast
  5.4.6 Japan
    5.4.6.1 Market size and forecast
  5.4.9 Rest of Asia-Pacific
    5.4.9.1 Market size and forecast
5.5 LAMEA
  5.5.1 Key market trends
  5.5.2 Key growth factors and opportunities
  5.5.3 Market size and forecast
  5.5.4 Brazil
    5.5.4.1 Market size and forecast
  5.5.5 Israel
    5.5.5.1 Market size and forecast
  5.5.6 Saudi Arabia
    5.5.6.1 Market size and forecast
  5.5.7 South Africa
    5.5.7.1 Market size and forecast
  5.5.8 Rest of LAMEA
    5.5.8.1 Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1 BOSTON SCIENTIFIC CORPORATION
  6.1.1 Company Overview
  6.1.2 Company Snapshot
  6.1.3 Operating Business Segments
  6.1.4 Business Performance
  6.1.5 Key Strategic Moves & Developments
6.2 Direct Flow Medical, Inc.
  6.2.1 Company Overview
  6.2.2 Company Snapshot
  6.2.3 Operating Business Segments
  6.2.4 Key Strategic Moves & Developments
6.3 Edwards Lifesciences Corporation
  6.3.1 Company Overview
  6.3.2 Company Snapshot
  6.3.3 Operating Business Segments
  6.3.4 Business Performance
  6.3.5 Key Strategic Moves & Developments
6.4 HLT, Inc.
  6.4.1 Company Overview
  6.4.2 Operating Business Segments
6.5 JenaValve Technology, Inc.
  6.5.1 Company Overview
  6.5.2 Company Snapshot
  6.5.3 Operating Business Segments
6.6 Medtronic plc
  6.6.1 Company Overview
  6.6.2 Company Snapshot
  6.6.3 Operating Business Segments
  6.6.4 Business Performance
  6.6.5 Key Strategic Moves & Developments
6.7 Meril Life Sciences Pvt. Ltd.
  6.7.1 Company Overview
  6.7.2 Company Snapshot
  6.7.3 Operating Business Segments
6.8 St. Jude Medical, Inc.
  6.8.1 Company Overview
  6.8.2 Company Snapshot
  6.8.3 Operating Business Segments
  6.8.4 Business Performance
  6.8.5 Key Strategic Moves And Developments
6.9 SYMETIS SA
  6.9.1 Company Overview
  6.9.2 Company Snapshot
  6.9.3 Operating Business Segments
  6.9.4 Key Strategic Moves & Developments
6.10 Transcatheter Technologies GmbH
  6.10.1 Company Overview
  6.10.2 Company Snapshot
  6.10.3 Operating Business Segments
  6.10.4 Key Strategic Moves & Developments

List Of Tables

LIST OF TABLES

TABLE 1 MAJOR TAVI APPROVED DEVICES
TABLE 2 CLINICAL TRIALS, TAVI MARKET, 20122016
TABLE 3 WORLD TAVI MARKET, BY PROCEDURE, 20142022 ($MILLION)
TABLE 4 WORLD TAVI MARKET, BY PROCEDURE, 20142022 (UNITS)
TABLE 5 WORLD TAVI MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
TABLE 6 WORLD TAVI MARKET, BY GEOGRAPHY, 20142022 (UNITS)
TABLE 7 NORTH AMERICA TAVI MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 8 NORTH AMERICA TAVI MARKET, BY COUNTRY, 20142022 (UNITS)
TABLE 9 NORTH AMERICA TAVI MARKET, BY PROCEDURE, 20142022 ($MILLION)
TABLE 10 NORTH AMERICA TAVI MARKET, BY PROCEDURE, 20142022 (UNITS)
TABLE 11 EUROPE: TAVI MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 12 EUROPE: TAVI MARKET, BY COUNTRY, 20142022 (UNITS)
TABLE 13 EUROPE: TAVI MARKET, BY PROCEDURE, 2014-2022 ($MILLION)
TABLE 14 EUROPE: TAVI MARKET, BY PROCEDURE, 2014-2022 (UNITS)
TABLE 15 ASIA-PACIFIC: TAVI MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 16 ASIA-PACIFIC: TAVI MARKET, BY COUNTRY, 20142022 (UNITS)
TABLE 17 ASIA-PACIFIC: TAVI MARKET, BY PROCEDURE, 20142022 ($MILLION)
TABLE 18 ASIA-PACIFIC: TAVI MARKET, BY PROCEDURE, 20142022 (UNITS)
TABLE 19 LAMEA: TAVI MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 20 LAMEA: TAVI MARKET, BY COUNTRY, 20142022 (UNITS)
TABLE 21 LAMEA: TAVI MARKET, BY PROCEDURE, 20142022 ($MILLION)
TABLE 22 LAMEA: TAVI MARKET, BY PROCEDURE, 20142022 (UNITS)
TABLE 23 BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 24 BOSTON SCIENTIFIC: PRODUCT CATEGORIES
TABLE 25 DIRECT FLOW MEDICAL: COMPANY SNAPSHOT
TABLE 26 EDWARDS LIFESCIENCES: COMPANY SNAPSHOT
TABLE 27 EDWARDS LIFESCIENCES: PRODUCT CATEGORIES
TABLE 28 JENAVALVE-COMPANY SNAPSHOT
TABLE 29 MEDTRONIC-COMPANY SNAPSHOT
TABLE 30 MEDTRONIC: PRODUCT CATEGORIES
TABLE 31 MERIL LIFE SCIENCES: COMPANY SNAPSHOT
TABLE 32 MERIL LIFE SCIENCES: PRODUCT CATEGORIES
TABLE 33 ST. JUDE MEDICAL: COMPANY SNAPSHOT
TABLE 34 ST. JUDE MEDICAL: PRODUCT CATEGORIES
TABLE 35 SYMETIS: COMPANY SNAPSHOT
TABLE 36 TRANSCATHETER TECHNOLOGIES -COMPANY SNAPSHOT

List Of Figures

LIST OF FIGURES

FIG. 1 PORTERS FIVE FORCES ANALYSIS
FIG. 2 MARKET SHARE ANALYSIS, 2015
FIG. 3 TOP IMPACTING FACTORS: TRANSCATHETER AORTIC VALVE IMPLANTATION MARKET, 2014-2022
FIG. 4 AGE DISTRIBUTION OF TAVR PATIENTS, U.S., 2013
FIG. 5 U.S. TAVI MARKET, (20142022) ($MILLION)
FIG. 6 CANADA TAVI MARKET, (20142022) ($MILLION)
FIG. 7 MEXICO TAVI MARKET, (20142022) ($MILLION)
FIG. 8 GERMANY TAVI MARKET, (20142022) ($MILLION)
FIG. 9 FRANCE TAVI MARKET, (20142022) ($MILLION)
FIG. 10 U.K. TAVI MARKET, (20142022) ($MILLION)
FIG. 11 ITALY TAVI MARKET, (20142022) ($MILLION)
FIG. 12 SWITZERLAND TAVI MARKET, (20142022) ($MILLION)
FIG. 13 REST OF EUROPE TAVI MARKET, (20142022) ($MILLION)
FIG. 14 INDIA TAVI MARKET, (20142022) ($MILLION)
FIG. 15 CHINA TAVI MARKET, (20142022) ($MILLION)
FIG. 16 JAPAN TAVI MARKET, (20142022) ($MILLION)
FIG. 17 AUSTRALIA TAVI MARKET, (20142022) ($MILLION)
FIG. 18 SOUTH KOREA TAVI MARKET, (20142022) ($MILLION)
FIG. 19 REST OF ASIA-PACIFIC TAVI MARKET, (20142022) ($MILLION)
FIG. 20 LATIN AMERICA TAVI MARKET, (20142022) ($MILLION)
FIG. 21 ISRAEL TAVI MARKET, (20142022) ($MILLION)
FIG. 22 SAUDI ARABIA TAVI MARKET, (20142022) ($MILLION)
FIG. 23 SOUTH AFRICA TAVI MARKET, (20142022) ($MILLION)
FIG. 24 REST OF LAMEA TAVI MARKET, (20152022) ($MILLION)
FIG. 25 BOSTON SCIENTIFIC: NET SALES, 20132015 ($MILLION)
FIG. 26 BOSTON SCIENTIFIC: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 27 BOSTON SCIENTIFIC: CARDIOVASCULAR REVENUE, BY SUBSEGMENT, 2015 (%)
FIG. 28 BOSTON SCIENTIFIC: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 29 EDWARDS LIFESCIENCES: NET SALES, 20132015 ($MILLION)
FIG. 30 EDWARDS LIFESCIENCES: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 31 EDWARDS LIFESCIENCES: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 32 MEDTRONIC: NET SALES, 20142016 ($MILLION)
FIG. 33 MEDTRONIC: REVENUE, BY SEGMENT, 2016 (%)
FIG. 34 MEDTRONIC: CARDIAC AND VASCULAR GROUP REVENUE, BY SUBSEGMENT, 2016 (%)
FIG. 35 MEDTRONIC: REVENUE, BY GEOGRAPHY, 2016 (%)
FIG. 36 ST. JUDE MEDICAL: NET SALES, 20132015, ($MILLION)
FIG. 37 ST. JUDE MEDICAL: REVENUE BY PRODUCT CATEGORIES, 2015 (%)
FIG. 38 ST. JUDE MEDICAL: REVENUE BY GEOGRAPHY, 2015 (%)